Clinical trials: Proteinuric Kidney Diseases
Proteinuric Kidney Disease
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
- Trial name
- AMPLITUDE (NCT05312879)
- Testing
- VX-147
- Where
- 314 sites in United States, Belgium and 11 more
- Volunteers
- 522 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Proteinuria
Belatacept Conversion in Proteinuric Kidney Transplant Recipients
Background: Proteinuria develops in about 30% of kidney transplant recipients and is a strong predictor of graft loss. The amount of proteinuria has a direct correlation with the risk of graft failure.
- Trial name
- NCT02327403
- Testing
- Belatacept
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Brigham and Women's Hospital
Proteinuria
Effect of Oral Supplementation With Curcumin in Patients With Proteinuric Diabetic Kidney Disease
The purpose of this study is to determine if the oral supplementation with curcumin reduces proteinuria, improves the redox and pro-inflammatory state in patients with chronic kidney disease associated to Diabetes mellitus.
- Trial name
- NCT03019848
- Testing
- Curcumin
- Where
- Mexico
- Volunteers
- 100 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Proteinuria
Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients
Proteinuria is not only a marker of chronic kidney disease (CKD) progression, but also a marker of cardiovascular disease and death.
- Trial name
- NCT01512862
- Testing
- Calcitriol
- Where
- 3 sites in South Korea
- Volunteers
- 240 people
- Sponsor
- Seoul National University Hospital